GlassScriptPhysician profile
Pamela B Dudkiewicz
NPI 1982765855
$88,602.51
in general payments reported to CMS, 2019-2025
29 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30K · 2022: $18K · 2023: $16K · 2024: $2,966 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $7,303 · Consulting Fee: $5,055 · Food and Beverage: $4,755 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,267.09 |
| Travel and Lodging | $7,302.83 |
| Consulting Fee | $5,055.00 |
| Food and Beverage | $4,755.22 |
| Education | $297.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,593.02 | 2021-2025 | Calquence |
| Dova Pharmaceuticals | $15,966.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $9,504.81 | 2022-2024 | Pomalyst, Reblozyl |
| Pfizer INC. | $8,501.07 | 2024-2025 | |
| Amgen INC. | $8,340.47 | 2021-2025 | Nplate, Nplate |
| Seagen INC. | $7,474.04 | 2021-2023 | Adcetris |
| Sobi, INC | $4,225.23 | 2022 | |
| Celgene Corporation | $1,500.45 | 2021-2025 | Reblozyl |
| Adc Therapeutics America, INC. | $900.00 | 2022 | |
| Kyowa Kirin, INC. | $825.19 | 2021-2024 | Poteligeo |
| Adaptive Biotechnologies Corporation | $701.60 | 2023-2025 | Clonoseq |
| Janssen Biotech, INC. | $587.91 | 2021-2025 | Rybrevant, Carvykti, Imbruvica |
| Janssen Pharmaceuticals, INC | $274.92 | 2021-2022 | |
| Beigene USA, INC. | $257.67 | 2024-2025 | Brukinsa |
| Genmab U.S., INC. | $224.71 | 2023-2024 | Epkinly |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $220.60 | 2022-2024 | |
| Legend Biotech USA INC. | $183.32 | 2024 | Carvykti |
| Genentech, INC. | $175.82 | 2024-2025 | Lunsumio, Columvi, Polivy |
| Lilly USA, LLC | $161.40 | 2024-2025 | Jaypirca |
| Lantheus Medical Imaging, INC. | $152.40 | 2021 | |
| Deciphera Pharmaceuticals INC. | $143.18 | 2025 | Qinlock |
| Exelixis INC. | $134.94 | 2021 | |
| Beone Medicines USA, INC. | $130.50 | 2025 | Brukinsa |
| Caris Mpi, INC. | $128.25 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $112.87 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $104.29 | 2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $42.23 | 2022-2025 | Ultomiris |
| Genentech USA, INC. | $18.16 | 2024 | Lunsumio, Polivy, Columvi |
| Blueprint Medicines Corporation | $17.02 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Dudkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.